| P2093 | author name string | Small S | |
| | Youseff N | |
| P2860 | cites work | Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen | Q28141785 |
| | Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group | Q28247583 |
| | Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group | Q28374428 |
| | A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts | Q32048820 |
| | Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide | Q41197059 |
| | A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group | Q41439111 |
| | Mechanisms and management of acute renal allograft rejection | Q41734033 |
| | A prospective randomized trial of FK506-based immunosuppression after renal transplantation | Q42411557 |
| | Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation | Q43453547 |
| | Risk factors for chronic rejection in renal allograft recipients. | Q43669281 |
| | Early versus late acute renal allograft rejection: impact on chronic rejection. | Q43824714 |
| | Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study | Q57943257 |
| | Sirolimus-tacrolimus combination immunosuppression | Q60998185 |
| | Renal transplantation | Q72442105 |
| | Dosing and management guidelines for tacrolimus in renal transplant patients | Q73214564 |
| | Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group | Q73253906 |
| | Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat | Q74015576 |
| | Sirolimus and cyclosporin for renal transplantation | Q74236870 |
| | Immunosuppressive agents: recent developments in molecular action and clinical application | Q74686279 |
| | Role of therapeutic drug monitoring of rapamycin | Q77176891 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1653-1655 | |
| P577 | publication date | 2002-08-01 | |
| P1433 | published in | Transplantation Proceedings | Q7834825 |
| P1476 | title | A retrospective analysis of a sirolimus/prograf regimen for the prevention of acute rejection in recipients of primary mismatched renal allografts | |
| P478 | volume | 34 | |